| [No authors listed]. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group[J]. N Engl J Med, 1995, 333:1581-1587. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke(ECASS II). Second European-Australasian Acute Stroke Study Investigators[J]. Lancet, 1998, 352:1245-1251. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study(SITS-MOST):an observational study[J]. Lancet, 2007, 369:275-282. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke[J]. N Engl J Med, 2008, 359:1317-1329. Brown DL, Barsan WG, Lisabeth LD, et al. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke[J]. Ann Emerg Med, 2005, 46:56-60. Libman R, Kwiakowski T, Lyden P, et al. Asymptomatic hemorrhagic transformation of cerebral infarction does not worsen long-term outcome[J]. J Stroke Cerebrovasc Dis, 2005, 14:50-54. Berger C, Fiorelli M, Steiner T, et al. Hemorrhagic transformation of ischemic brain tissue:asymptomatic or symptomatic?[J]. Stroke, 2001, 32:1330-1335. Strbian D, Sairanen T, Meretoja A, et al. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis[J]. Neurology, 2011, 77:341-348. Gumbinger C, Gruschka P, Bottinger M, et al. Improved prediction of poor outcome after thrombolysis using conservative definitions of symptomatic hemorrhage[J]. Stroke, 2012, 43:240-242. Mazya M, Egido JA, Ford GA, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase:Safe Implementation of Treatments in Stroke(SITS) symptomatic intracerebral hemorrhage risk score[J]. Stroke, 2012, 43:1524-1531. Menon B K, Saver JL, Prabhakaran S, et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator[J]. Stroke, 2012, 43:2293-2299. Strbian D, Engelter S, Michel P, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis:the SEDAN score[J]. Ann Neurol, 2012, 71:634-641. Saposnik G, Raptis S, Kapral M K, et al. The iScore predicts poor functional outcomes early after hospitalization for an acute ischemic stroke[J]. Stroke, 2011, 42:3421-3428. Saposnik G, Kapral MK, Liu Y, et al. IScore:a risk score to predict death early after hospitalization for an acute ischemic stroke[J]. Circulation, 2011, 123:739-749. Saposnik G, Fang J, Kapral MK, et al. The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke[J]. Stroke, 2012, 43:1315-1322. Lou M, Safdar A, Mehdiratta M, et al. The HAT Score:a simple grading scale for predicting hemorrhage after thrombolysis[J]. Neurology, 2008, 71:1417-1423 Cucchiara B, Tanne D, Levine SR, et al. A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke[J]. J Stroke Cerebrovasc Dis, 2008, 17:331-333. Prabhakaran S, Rivolta J, Vieira JR, et al. Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke[J]. Arch Neurol, 2010, 67:559-563. Seet RC, Zhang Y, Moore SA, et al. Subtherapeutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis[J]. Stroke, 2011, 42:2333-2335. Ruecker M, Matosevic B, Willeit P, et al. Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis[J]. Neurology, 2012, 79:31-38. Vergouwen MD, Casaubon LK, Swartz RH, et al. Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator[J]. Stroke, 2011, 42:1041-1045. De Marchis GM, Jung S, Colucci G, et al. Intracranial hemorrhage, outcome, and mortality after intra-arterial therapy for acute ischemic stroke in patients under oral anticoagulants[J]. Stroke, 2011, 42:3061-3066. Xian Y, Liang L, Smith EE, et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator[J]. JAMA, 2012, 307:2600-2608. Engelter ST, Soinne L, Ringleb P, et al. IV thrombolysis and statins[J]. Neurology, 2011, 77:888-895. Nardi K, Engelter S, Strbian D, et al. Lipid profiles and outcome in patients treated by intravenous thrombolysis for cerebral ischemia[J]. Neurology, 2012, 79:1101-1108. Qureshi AI, Chaudhry SA, Hassan AE, et al. Thrombolytic treatment of patients with acute ischemic stroke related to underlying arterial dissection in the United States[J]. Arch Neurol, 2011, 68:1536-1542. Edgell RC, Vora NA. Neuroimaging markers of hemorrhagic risk with stroke reperfusion therapy[J]. Neurology, 2012, 79:S100-S104. Singer OC, Kurre W, Humpich MC, et al. Risk assessment of symptomatic intracerebral hemorrhage after thrombolysis using DWI-ASPECTS[J]. Stroke, 2009, 40:2743-2748. Lin K, Zink WE, Tsiouris AJ, et al. Risk assessment of hemorrhagic transformation of acute middle cerebral artery stroke using multimodal CT[J]. J Neuroimaging, 2012, 22:160-166. Lansberg MG, Thijs VN, Bammer R, et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke[J]. Stroke, 2007, 38:2275-2278. Audebert HJ, Singer OC, Gotzler B, et al. Postthrombolysis hemorrhage risk is affected by stroke assessment bias between hemispheres[J]. Neurology, 2011, 76:629-636. Campbell BC, Christensen S, Butcher KS, et al. Regional very low cerebral blood volume predicts hemorrhagic transformation better than diffusion-weighted imaging volume and thresholded apparent diffusion coefficient in acute ischemic stroke[J]. Stroke, 2010, 41:82-88. Aviv RI, D'Esterre CD, Murphy BD, et al. Hemorrhagic transformation of ischemic stroke:prediction with CT perfusion[J]. Radiology, 2009, 250:867-877. Neumann-Haefelin T, Hoelig S, Berkefeld J, et al. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke[J]. Stroke, 2006, 37:2463-2466. Hjort N, Wu O, Ashkanian M, et al. MRI detection of early blood-brain barrier disruption:parenchymal enhancement predicts focal hemorrhagic transformation after thrombolysis[J]. Stroke, 2008, 39:1025-1028. Saqqur M, Tsivgoulis G, Molina CA, et al. Symptomatic intracerebral hemorrhage and recanalization after IV rt-PA:a multicenter study[J]. Neurology, 2008, 71:1304-1312. Jickling GC, Sharp FR. Blood biomarkers of ischemic stroke[J]. Neurotherapeutics, 2011, 8:349-360. Nafria C, Fernandez-Cadenas I, Mendioroz M, et al. Update on the serum biomarkers and genetic factors associated with safety and efficacy of rt-PA treatment in acute stroke patients[J]. Stroke Res Treat, 2011, 2011:182783. Nafria C, Fernandez-Cadenas I, Mendioroz M, et al. Update on the serum biomarkers and genetic factors associated with safety and efficacy of rt-PA treatment in acute stroke patients[J]. Stroke Res Treat, 2011, 2011:182783. Laskowitz DT, Kasner SE, Saver J, et al. Clinical usefulness of a biomarker-based diagnostic test for acute stroke:the Biomarker Rapid Assessment in Ischemic Injury(BRAIN) study[J]. Stroke, 2009, 40:77-85. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes:novel derivation method and application to thrombolytic therapy for acute stroke[J]. Arch Neurol, 2004, 61:1066-1070. Saver JL. Hemorrhage after thrombolytic therapy for stroke:the clinically relevant number needed to harm[J]. Stroke, 2007, 38:2279-2283. |
